Combination therapy of cyclophosphamide and Rhizoma Paridis Saponins on anti-hepatocarcinoma mice and effects on cytochrome p450 enzyme expression

Steroids

Volumn 80, Issue , 2014, Pages 1-6

  Man, Shuli ^a   Li, Yuanyuan ^a   Fan, Wei ^a   Gao, Wenyuan ^a,b   Liu, Zhen ^b   Zhang, Yao ^b   Liu, ChangXiao ^c  

^a TIANJIN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b TIANJIN UNIVERSITY   (China)

^c TIANJIN INSTITUTE OF PHARMACEUTICAL RESEARCH   (China)

Author keywords

Cyclophosphamide; CYP; Herb drug interactions; Rhizoma Paridis Saponins

Indexed keywords

AMFEBUTAMONE; CHLORZOXAZONE; COUMARIN; CYCLOPHOSPHAMIDE; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2A6; CYTOCHROME P450 2B6; CYTOCHROME P450 2C9; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; DAPSONE; PHENACETIN; RHIZOMA PARIDIS SAPONIN; SAPONIN; TOLBUTAMIDE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CYTOCHROME P450 INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DRUG EFFECT; DRUG MEGADOSE; ENZYME ACTIVITY; FEMALE; HERB DRUG INTERACTION; IN VIVO STUDY; LIVER CELL CARCINOMA; LIVER MICROSOME; LOW DRUG DOSE; MOUSE; NONHUMAN; PARIS POLYPHYLLA; PROTEIN EXPRESSION; RAT; ANIMAL; BIOSYNTHESIS; BLOOD; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; DRUG SCREENING; INBRED MOUSE STRAIN; LIVER NEOPLASMS; METABOLISM; NEOPLASMS, EXPERIMENTAL; PATHOLOGY; RHIZOME; SPRAGUE DAWLEY RAT; STRUCTURE ACTIVITY RELATION;

MUS; RATTUS;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; CYCLOPHOSPHAMIDE; CYTOCHROME P-450 ENZYME INHIBITORS; CYTOCHROME P-450 ENZYME SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; LIVER NEOPLASMS; MICE; MICE, INBRED STRAINS; NEOPLASMS, EXPERIMENTAL; RATS; RATS, SPRAGUE-DAWLEY; RHIZOME; SAPONINS; STRUCTURE-ACTIVITY RELATIONSHIP; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84890283042     PISSN: 0039128X     EISSN: 18785867     Source Type: Journal    
DOI: 10.1016/j.steroids.2013.11.015     Document Type: Article

References (14)

1. C.D. Scripture, A. Sparreboom, and W.D. Figg Modulation of cytochrome P450 activity: implications for cancer therapy Lancet Oncol 6 2005 780 789. (Pubitemid 41430719)
2. H.I. Su, M.D. Sammel, L. Velders, M. Horn, C. Stankiewicz, and J. Matro Association of cyclophosphamide drug-metabolizing enzyme polymorphisms and chemotherapy-related ovarian failure in breast cancer survivors Fertil Steril 94 2010 645 654.
3. H. Lu, and K.K. Chan Pharmacokinetics of N-2-chloroethylaziridine, a volatile cytotoxic metabolite of cyclophosphamide, in the rat Cancer Chemother Pharmacol 58 2006 532 539. (Pubitemid 43999803)
4. X. Wang, J. Zhang, and T. Xu Cyclophosphamide as a potent inhibitor of tumor thioredoxin reductase in vivo Toxicol Appl Pharmacol 218 2007 88 95. (Pubitemid 46026846)
5. W. Li, S. Nie, Y. Chen, Y. Wang, C. Li, and M. Xie Enhancement of cyclophosphamide-induced antitumor effect by a novel polysaccharide from ganoderma atrum in sarcoma 180-bearing mice J. Agric. Food Chem. 59 2011 3707 3716.
6. J. Wang, X. Tong, P. Li, H. Cao, and W. Su Immuno-enhancement effects of Shenqi Fuzheng injection on cyclophosphamide-induced immunosuppression in balb/c mice J Ethnopharmacol 139 2012 788 795.
7. S.L. Man, Y.J. Zhang, W.Y. Gao, L.L. Yan, and C.Y. Ma Cyclophosphamide promotes pulmonary metastasis on mouse lung adenocarcinoma Clin Exp Metastasis 25 2008 855 864.
8. S. Man, W. Gao, Y. Zhang, L. Yan, C. Ma, and C. Liu Antitumor and antimetastatic activities of Rhizoma Paridis Saponins Steroids 74 2009 1051 1056.
9. S. Man, W. Gao, Y. Zhang, X. Jin, C. Ma, and X. Huang Characterization of steroidal saponins in saponin extract from Paris polyphylla by liquid chromatography tandem multi-stage mass spectrometry Anal Bioanal Chem 395 2009 495 505.
10. T. Ishida, E. Shiraga, and H. Kiwada Synergistic antitumor activity of metronomic dosing of cyclophosphamide in combination with doxorubicin-containing PEGylated liposomes in a murine solid tumor model J Control Release 134 2009 194 200.
11. G.C. Huang, L.S. Wu, L.G. Chen, L.L. Yang, and C.C. Wang Immuno-enhancement effects of Huang Qi Liu Yi Tang in a murine model of cyclophosphamide-induced leucopenia J Ethnopharmacol 109 2007 229 235.
12. C. Ekhart, S. Rodenhuis, P.H. Smits, J.H. Beijnen, and A.D. Huitema Relations between polymorphisms in drug-metabolising enzymes and toxicity of chemotherapy with cyclophosphamide, thiotepa and carboplatin Pharmacogenet Genomics 18 2008 1009 1015.
13. C. Ekhart, V.D. Doodeman, S. Rodenhuis, P.H. Smits, J.H. Beijnen, and A.D. Huitema Influence of polymorphisms of drug metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and ALDH3A1) on the pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide Pharmacogenet Genomics 18 2008 515 523. (Pubitemid 351769919)
14. C. Lindley, G. Hamilton, J.S. McCune, S. Faucette, S.S. Shord, and R.L. Hawke The effect of cyclophosphamide with and without dexamethasone on cytochrome P450 3A4 and 2B6 in human hepatocytes Drug Metab. Dispos. 30 2002 814 822. (Pubitemid 34671094)